Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1

被引：0

作者：

Orkin, C. ^{[1
]}

Molina, J. ^{[2
]}

Yazdanpanah, Y. ^{[3
]}

Chahin Anania, C. ^{[4
]}

DeJesus, E. ^{[5
]}

Eron, J. ^{[6
]}

Klopfer, S. ^{[7
]}

Grandhi, A. ^{[7
]}

Xu, J. ^{[7
]}

Eves, K. ^{[7
]}

Hepler, D. ^{[7
]}

Robertson, M. ^{[7
]}

Hwang, C. ^{[7
]}

Hanna, G. ^{[7
]}

Correll, T. ^{[7
]}

机构：

[1] Queen Mary Univ London, HIV Med, London, England

[2] St Louis Hosp & Univ, Infect Dis, Paris, France

[3] Hop Xavier Bichat, Infect Dis, Paris, France

[4] Hosp Hernan, Infectol Unit, Temuco, Chile

[5] Orlando Immunol Ctr, Infect Dis, Orlando, FL USA

[6] Univ N Carolina, Infect Dis, Chapel Hill, NC 27515 USA

[7] Merck & Co Inc, Res, Kenilworth, NJ USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P047

引用

页码：51 / 52

页数：2

共 16 条

[1] Renal safety through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1
Post, F.
McMullan, C.
DiPerri, G.
Molina, J.
Klopfer, S.
Grandhi, A.
Eves, K.
Hepler, D.
Hwang, C.
Correll, T.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 52 - 52
[2] Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection
Orkin, C.
Molina, J. -M.
Yazdanpanah, Y.
Anania, C. Chahlin
DeJesus, E.
Eron, J.
Klopfer, S.
Grandhi, A.
Eves, K.
Rudd, D.
Robertson, M.
Sklar, P.
Hwang, C.
Hanna, G.
Correll, T.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 15 - 16
[3] Efficacy and safety of islatravir in combination with doravirine through 144 weeks for treatment-naive adults with HIV-1 infection in a phase 2b trial
Molina, J. -M.
Yazdanpanah, Y.
Saud, A. Afani
Bettacchi, C.
Anania, C. Chahin
Klopfer, S. Olsen
Grandhi, A.
Eves, K.
Hepler, D.
Lahoulou, R.
Correll, T.
HIV MEDICINE, 2021, 22 : 6 - 7
[4] Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
Molina, Jean-Michel
Yazdanpanah, Yazdan
Afani Saud, Alejandro
Bettacchi, Christopher
Chahin Anania, Carolina
Klopfer, Stephanie O.
Grandhi, Anjana
Eves, Karen
Hepler, Deborah
Robertson, Michael N.
Hwang, Carey
Hanna, George J.
Correll, Todd
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (01) : 68 - 72
[5] Islatravir safety analysis through week 96 from a Phase 2 trial in treatment naive adults with HIV-1 infection
Cunningham, D.
Molina, J-M
Yazdanpanah, Y.
Saud, A. A.
Anania, C. C.
Klopfer, S. O.
Grandhi, A.
Eves, K.
Hepler, D.
Hwang, C.
Lahoulou, R.
Correll, T. A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 23 - 23
[6] Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
Molina, Jean-Michel
Yazdanpanah, Yazdan
Saud, Alejandro
Bettacchi, Christopher
Anania, Carolina
Dejesus, Edwin
Klopfer, Stephanie
Grandhi, Anjana
Eves, Karen
Robertson, Michael
Correll, Todd
Hwang, Carey
Hanna, George
Sklar, Peter
LANCET HIV, 2021, 8 (06): : E324 - E333
[7] Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection
DeJesus, E.
Molina, J. -M.
Yazdanpanah, Y.
Afani Saud, A.
Bettacchi, C.
Chahin Anania, C.
Klopfer, S.
Grandhi, A.
Eves, K.
Robertson, M.
Sklar, P.
Hwang, C.
Hanna, G.
Correll, T.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 17 - 17
[8] Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naive adults with HIV-1 infection
Molina, J-M
Yazdanpanah, Y.
Afani Saud, A.
Bettacchi, C.
Chahin Anania, C.
DeJesus, E.
Klopfer, S.
Grandhi, A.
Eves, K.
Robertson, M.
Correll, T.
Hwang, C.
Hanna, G.
Sklar, P.
HIV MEDICINE, 2019, 20 : 97 - 97
[9] MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naive adults with HIV-1 infection
Molina, J. -M.
Yazdanpanah, Y.
Saud, A. Afani
Bettacchi, C.
Anania, C. Chahin
DeJesus, E.
Klopfer, S. O.
Eves, K.
Grandhi, A.
Robertson, M. N.
Hwang, C.
Hanna, G.
Sklar, P.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 102 - 102
[10] Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTE study
Ackerman, P.
Gartland, M.
Chabria, S.
Mannino, F.
Garside, L.
Kustra, R.
Clark, A.
Pierce, A.
Krystal, M.
Llamoso, C.
Lataillade, M.
HIV MEDICINE, 2019, 20 : 190 - 191

← 1 2 →